TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy

BACKGROUND: Combination antiretroviral therapy results in metabolic abnormalities which increase cardiovascular disease risk. We evaluated whether telmisartan reduces insulin resistance in human immunodeficiency virus (HIV)–positive individuals on antiretrovirals. METHODS: We conducted a multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales: Pushpakom, Sudeep, Kolamunnage-Dona, Ruwanthi, Taylor, Claire, Foster, Terry, Spowart, Cath, García-Fiñana, Marta, Kemp, Graham J, Jaki, Thomas, Khoo, Saye, Williamson, Paula, Pirmohamed, Munir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201422/
https://www.ncbi.nlm.nih.gov/pubmed/31425580
http://dx.doi.org/10.1093/cid/ciz589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201422/
https://www.ncbi.nlm.nih.gov/pubmed/31425580
http://dx.doi.org/10.1093/cid/ciz589

Ejemplares similares